What's Happening?
Eli Lilly and Company is seeking a Scientific Lead for its Molecular Characterization team within Discovery Technologies. This role focuses on developing and optimizing spatial biology and long-read genomics platforms to support oncology drug discovery.
The team operates at the intersection of genomics, proteomics, and emerging molecular technologies, aiming to enhance Lilly's discovery portfolio. The position requires expertise in spatial transcriptomics and long-read sequencing, with responsibilities including the integration of spatial transcriptomics with proteomics and single-cell data, and the development of image analysis pipelines. The role also involves scaling long-read sequencing workflows and automating NGS and spatial library preparation protocols.
Why It's Important?
The advancement of spatial biology and genomics is crucial for the development of targeted cancer therapies. By enhancing the understanding of molecular interactions within tissues, these technologies can lead to more effective oncology treatments. Eli Lilly's focus on integrating these advanced platforms into their drug discovery process highlights the growing importance of precision medicine. This development could potentially accelerate the discovery of new cancer treatments, benefiting patients and the healthcare industry. The role also emphasizes the need for continuous innovation and adaptation of emerging technologies in the pharmaceutical sector.
What's Next?
Eli Lilly is likely to continue investing in cutting-edge technologies to maintain its competitive edge in oncology drug discovery. The successful implementation of these platforms could lead to collaborations with academic institutions and technology vendors, further expanding Lilly's capabilities. As the platforms mature, there may be opportunities to mentor junior scientists and shape the scientific direction of the team. The integration of these technologies into Lilly's research pipeline could result in the development of new cancer therapies, potentially leading to clinical trials and regulatory approvals.
